



OPEN ACCESS

EDITED AND REVIEWED BY
Justin Lathia,
Case Western Reserve University,
United States

*CORRESPONDENCE

Qing Liu
✉ liuqingdr@csu.edu.cn
Rongfu Wang
✉ rongfuwa@usc.edu

†These authors have contributed equally to
this work

SPECIALTY SECTION

This article was submitted to
Neuro-Oncology and
Neurosurgical Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 02 February 2023

ACCEPTED 27 February 2023

PUBLISHED 22 March 2023

CITATION

Ma Q, Long W, Xing C, Jiang C, Su J,
Wang HY, Liu Q and Wang R (2023)
Corrigendum: PHF20 promotes
glioblastoma cell malignancies through a
WISP1/BGN-dependent pathway.
Front. Oncol. 13:1157694.
doi: 10.3389/fonc.2023.1157694

COPYRIGHT

© 2023 Ma, Long, Xing, Jiang, Su, Wang, Liu
and Wang. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: PHF20 promotes glioblastoma cell malignancies through a *WISP1/BGN*-dependent pathway

Qianqian Ma^{1,2,3†}, Wenyong Long^{1†}, Changsheng Xing⁴,
Chongming Jiang³, Jun Su¹, Helen Y. Wang⁴, Qing Liu^{1*}
and Rongfu Wang^{3,4,5,6*}

¹Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China, ²Department of Neurosurgery in the Third Hospital of Peking University, Peking University, Beijing, China, ³Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, United States, ⁴Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, ⁵Department of Pediatrics, Children's Hospital of Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, ⁶Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

KEYWORDS

PHF20, glioblastoma, *WISP1*, *BGN*, cancer stem cell-like traits, epigenetic regulation

A Corrigendum on

[PHF20 promotes glioblastoma cell malignancies through a *WISP1/BGN*-dependent pathway](#)

by Ma Q, Long W, Xing C, Jiang C, Su J, Wang HY, Liu Q, and Wang R-F (2020). *Front. Oncol.* 10:573318. doi: 10.3389/fonc.2020.573318

In the original article, there was an error in [Figure 1](#) as published. In [Figure 1C](#), the images labeled “PHF20 KO2” and “PHF20 KO3” in the row for “BT115” show an overlapping field of view. The corrected version of [Figure 1](#) and its caption appears below.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1
 PHF20 is highly expressed in GBM, and increases cellular viability, proliferation and invasiveness of GBM cells *in vitro* and *in vivo*. **(A)** Demonstration of ablation of PHF20 in BT115 and U87 GBM PHF20 KO cells by western blotting analysis. PHF20 KO clones were generated with PHF20 sgRNA #1, #2, and #3. Cells transfected with non-specific sgRNA were used as control. **(B)** A total of 5,000 wild-type (WT) and PHF20 KO BT115 cells and 10,000 WT and PHF20 KO U87 cells were plated in a 96-well plate using 200 μ l medium. Cell viability was assayed using an MTT assay (540 nm). Both PHF20 KO BT115 and U87 cells showed significantly reduced cell viability compared to control. **(C)** PHF20 KO and its control cells were subjected to transwell Matrigel invasion assays. Scale bar, 50 μ m. **(D)** The quantification of migrated cells through Matrigel for each cell line. Scale bar, 100 μ m. **(E)** A tumor sphere formation assay was performed to assess the self-renewal capacity of WT and PHF20 KO cells. Five random wells were photographed. **(F)** The quantification of the sphere number after 7 days for each cell line. **(G)** Representative xenografts excised from PHF20 KO and control groups of NSG mice (n = 5). **(H)** Growth of tumors following the subcutaneous injection of PHF20 KO and control cells. **(I)** The tumor weight of subcutaneous xenografts formed by U87 WT and PHF20 KO cells. The knockout group is remarkably decreased the tumor volume and weight. **(J)** IHC staining of PHF20 and Ki-67 of xenografts. Scale bar, 50 μ m. Data are plotted as the mean \pm SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 compared to the controls using Student's t-test.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.